Veliparib

• UNSPSC Description:

  Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively[1].

• Target Antigen:

  Autophagy; PARP

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Veliparib.html

• Purity:

  99.78

• Solubility:

  DMSO : ≥ 29 mg/mL

• Smiles:

  O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N

• Molecular Weight:

  244.298

• References & Citations:

  [1]Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37.|[2]Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201.|[3]Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890.Acta Pharmacol Sin. 2021 Jul 22.|Biomed Res Int. 2023 Feb 6.|BMC Cancer. 2022 Mar 23;22(1):312.|Cancer Discov. 2017 Sep;7(9):984-998.|Cancer Genet. 2019 Nov;239:26-32.|Cancers (Basel). 2024 Oct 10;16(20):3441.|Cells. 2021, 10(3), 599.|Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. |Ecotoxicol Environ Saf. 2023 Mar 1;252:114630.|Front Mol Biosci. 2021 Apr 29;8:633344.|Front Oncol. 2021 Jul 9;11:681441.|Int J Biol Macromol. 2023 May 12;124794.|J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195.|J Invest Dermatol. 2024 May 30:S0022-202X(24)00384-1.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. |Mol Cancer Ther. 2019 Nov;18(11):2063-2073.|Nanomaterials. 2021, 11(6), 1514.|Nat Commun. 2021 Jun 24;12(1):3931.|Neoplasia. 2018 Mar 28;20(5):478-488. |Neoplasia. 2019 Apr 24;21(6):533-544. |Oncogene. 2022 Aug 6.|Patent. US20180263995A1.|Patent. US20180362972A1.|Research Square Preprint. 2021 Feb.|Research Square Preprint. 2024 Feb 21.|Research Square Preprint. 2024 Nov 06.|Theranostics. 2020 Jul 25;10(21):9477-9494. |Electrostatics Joint Conference. 2016 July.|Harvard Medical School LINCS LIBRARY|Int J Curr Res Acad Rev. 2017; 5(3): 53-64.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Patent. US20200078369A1|Patent. US20200129476A1

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  912444-00-9